[CAS NO. 389139-89-3] Omadacycline
PRODUCTS SPECIFICATIONS [389139-89-3]
DESCRIPTION [389139-89-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 556.65 |
| Molecular Formula | C29H40N4O7 |
| SMILES | O=C(C1=C(O)[C@@H](N(C)C)[C@@](C[C@@]2([H])C(C(C3=C(O)C(CNCC(C)(C)C)=CC(N(C)C)=C3C2)=O)=C4O)([H])[C@@]4(O)C1=O)N |
19 Publications Citing Use of MCE
- [1]Nat Microbiol. 2023 Mar;8(3):410-423.
- [2]Nat Struct Mol Biol. 2023 Aug 7.
- [3]PLoS Biol. 2022 Sep 28;20(9):e3001808.
- [4]J Clin Microbiol. 2020 Jan 28;58(2):e01603-19.
- [5]Virulence. 2022 Dec;13(1):77-88.
- [6]J Antimicrob Chemother. 2021 May 6;dkab141.
- [7]J Antimicrob Chemother. 2021 Feb 11;76(3):653-658.
- [8]Antimicrob Agents Chemother. 2023 Jan 23;e0145922.
- [9]Ann Lab Med. 2021 May 1;41(3):293-301.
- [10]Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02097-19.
- [11]Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00470-19.
- [12]Antibiotics (Basel). 2022, 11(10), 1298.
- [13]Microbiol Spectr. 2023 May 4;e0071823.
- [14]Microbiol Spectr. 2022 Dec 8;e0323822.
- [15]J Antibiot (Tokyo). 2022 Jun 27.
- [16]Animal Feed Science and Technology. 2014 Dec;198:323-332.
- [17]Clin Exp Pharmacol Physiol. 2023 Apr 22.
- [18]Diagn Micr Infec Dis. 2020 Nov;98(3):115129.
- [19]Research Square Preprint. 2020 Jun.
Summary
Omadacycline (PTK 0796), a first-in-class orally active aminomethylcycline antibacterial , is a member of the tetracycline class of antibiotics . Omadacycline acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections [1] [2] [3] [4] .
IC50 & Target
|
Tetracycline |
In Vitro
Omadacycline displays activity against methicillin-resistant
Staphylococcus aureus
(MRSA), vancomycin-resistant
Enterococcus
(VRE), beta-hemolytic streptococci, penicillin-resistant
Streptococcus pneumonia
(PRSP) and
Haemophilus influenzae (H. influenzae)
, with MIC
90
s of 1.0, 0.25, 0.5, 0.25 and 2.0 μg/mL respectively
[2]
.
Omadacycline is active against strains expressing
tetracycline
and other
antibiotics
resistance by ribosomal protection and active
tetracycline
efflux
[2]
.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Omadacycline (0.11-18 mg/kg; a single i.v.) exhibits efficacy against Streptococcus pneumonia , Escherichia coli , and Staphylococcus aureus in mice systemic infection model, with ED 50 s ranging from 0.30 mg/kg to 3.39 mg/kg [2] .
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04160260 | Paratek Pharmaceuticals Inc |
Community-acquired Pneumonia
|
November 28, 2019 | Phase 1 |
| NCT00876850 | Paratek Pharmaceuticals Inc |
Skin Structures and Soft Tissue Infections
|
July 2009 | Phase 3 |
| NCT05217537 | Paratek Pharmaceuticals Inc |
Bacterial Infections
|
April 6, 2022 | Phase 1 |
| NCT04714411 | Methodist Health System |
Diabetic Foot Infection
|
November 5, 2020 | |
| NCT04922554 | Paratek Pharmaceuticals Inc |
Mycobacterium Infections, Nontuberculous|Mycobacterium Abscessus Infection|Nontuberculous Mycobacterial Lung Disease|Nontuberculous Mycobacterial Pulmonary Infection
|
October 15, 2021 | Phase 2 |
| NCT02531438 | Paratek Pharmaceuticals Inc |
Bacterial Pneumonia|Community-Acquired Infections
|
November 2015 | Phase 3 |
| NCT04779242 | Paratek Pharmaceuticals Inc |
Community-acquired Pneumonia|Bacterial Pneumonia
|
February 25, 2021 | Phase 3 |
| NCT03425396 | Paratek Pharmaceuticals Inc |
Uncomplicated Urinary Tract Infection|Cystitis
|
January 4, 2018 | Phase 2 |
| NCT03757234 | Paratek Pharmaceuticals Inc |
Acute Pyelonephritis
|
November 19, 2018 | Phase 2 |
| NCT04144374 | Hartford Hospital|Paratek Pharmaceuticals Inc |
Diabetes|Wound Infection|Healthy Volunteers
|
February 10, 2020 | Phase 1 |
| NCT03716024 | Paratek Pharmaceuticals Inc |
Infectious Skin Disease|Bacterial Skin Disease
|
July 18, 2007 | Phase 2 |
| NCT00865280 | Paratek Pharmaceuticals Inc|Novartis Pharmaceuticals |
Skin Diseases, Infectious
|
April 4, 2009 | Phase 3 |
| NCT02378480 | Paratek Pharmaceuticals Inc |
Bacterial Infections|Skin Structures and Soft Tissue Infections
|
June 2015 | Phase 3 |
| NCT02877927 | Paratek Pharmaceuticals Inc |
Bacterial Infections|Skin Structures and Soft Tissue Infections
|
August 2016 | Phase 3 |
| NCT05753215 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Paratek Pharmaceuticals Inc |
Bone Infection|Joint Infection|Bone and Joint Infection
|
May 9, 2023 | Phase 2 |
| NCT04460586 | Paul Beringer|Paratek Pharmaceuticals Inc|University of Southern California |
Cystic Fibrosis
|
July 1, 2021 | Phase 4 |
| NCT05515562 | Wake Forest University Health Sciences|University of Houston|High Point University|Paratek Pharmaceuticals Inc |
Microbial Colonization
|
March 20, 2023 | Phase 4 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
DMSO : 125 mg/mL ( 224.56 mM ; Need ultrasonic)
Methanol : 125 mg/mL ( 224.56 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.7965 mL | 8.9823 mL | 17.9646 mL |
| 5 mM | 0.3593 mL | 1.7965 mL | 3.5929 mL |
| 10 mM | 0.1796 mL | 0.8982 mL | 1.7965 mL |
References
- [1] Durães F, et, al. Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines. Pharmaceuticals (Basel). 2019 Apr 21;12(2):63.
- [2] Macone AB, et, al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58(2):1127-35.
- [3] Zhanel GG, et, al. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. Drugs. 2020 Feb;80(3):285-313.
- [4] Markham A, et, al. Omadacycline: First Global Approval. Drugs. 2018 Dec;78(18):1931-1937.